BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taber DJ, Su Z, Fleming JN, McGillicuddy JW, Posadas-Salas MA, Treiber FA, Dubay D, Srinivas TR, Mauldin PD, Moran WP. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017;101:2931-2938. [PMID: 28658199 DOI: 10.1097/tp.0000000000001840] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Park Y, Lee H, Eum SH, Kim HD, Ko EJ, Yang CW, Chung BH. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation. Front Immunol 2021;12:746013. [PMID: 34659243 DOI: 10.3389/fimmu.2021.746013] [Reference Citation Analysis]
2 Lenain R, Maanaoui M, Hamroun A, Larrue R, Van Der Hauwaert C, Gibier JB, Gnemmi V, Gomis S, Labalette M, Broly F, Hennart B, Pottier N, Hazzan M, Cauffiez C, Glowacki F. Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study. J Pers Med 2021;11:1002. [PMID: 34683143 DOI: 10.3390/jpm11101002] [Reference Citation Analysis]
3 Faravardeh A, Akkina S, Villicana R, Guerra G, Moten MA, Meier-Kriesche U, Stevens DR, Patel SJ, Bunnapradist S. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial. Ann Transplant 2021;26:e929535. [PMID: 33859155 DOI: 10.12659/AOT.929535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 McGillicuddy JW, Chandler JL, Sox LR, Taber DJ. Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Ann Pharmacother 2020;54:1185-93. [PMID: 32506922 DOI: 10.1177/1060028020931806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 2018;32:e13424. [PMID: 30318646 DOI: 10.1111/ctr.13424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
6 Zhang H, De T, Zhong Y, Perera MA. The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation? Clin Pharmacol Ther 2019;106:338-49. [PMID: 31038731 DOI: 10.1002/cpt.1491] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
7 Serper M, Ladner DP, Curtis LM, Nair SS, Hur SI, Kwasny MJ, Ho B, Friedewald J, Reese PP, Abecassis MMI, Wolf MS. Transplant regimen adherence for kidney recipients by engaging information technologies (TAKE IT): Rationale and methods for a randomized controlled trial of a strategy to promote medication adherence among transplant recipients. Contemp Clin Trials 2021;103:106294. [PMID: 33515781 DOI: 10.1016/j.cct.2021.106294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Grinyó JM. Renal allograft performance in immigrant transplant recipients. Transpl Int 2020;33:1387-9. [PMID: 32668492 DOI: 10.1111/tri.13702] [Reference Citation Analysis]
9 Kim J, Wilson S, Undre NA, Shi F, Kristy RM, Schwartz JJ. A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation. Drugs R D 2019;19:201-12. [PMID: 31073875 DOI: 10.1007/s40268-019-0271-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Sablik KA, Clahsen-van Groningen MC, Hesselink DA, van Gelder T, Betjes MGH. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS One 2018;13:e0196552. [PMID: 29746495 DOI: 10.1371/journal.pone.0196552] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
11 Pierce DR, West-Thielke P, Hajjiri Z, Gaitonde S, Tzvetanov I, Benedetti E, Lichvar AB. Clinical Implications of Tacrolimus Time in Therapeutic Range and Intrapatient Variability in Urban Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal. Transplant Direct 2021;7:e698. [PMID: 34036168 DOI: 10.1097/TXD.0000000000001155] [Reference Citation Analysis]
12 Yin S, Song T, Jiang Y, Li X, Fan Y, Lin T. Tacrolimus Trough Level at the First Month May Predict Renal Transplantation Outcomes Among Living Chinese Kidney Transplant Patients: A Propensity Score-Matched Analysis. Ther Drug Monit 2019;41:308-16. [PMID: 31083041 DOI: 10.1097/FTD.0000000000000593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Taber DJ, Hirsch J, Keys A, Su Z, McGillicuddy JW. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. Ther Drug Monit 2021;43:401-7. [PMID: 33560095 DOI: 10.1097/FTD.0000000000000863] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 McGillicuddy J, Chandler J, Sox L, Mueller M, Nemeth L, Baliga P, Treiber F. "Smartphone Medication Adherence Saves Kidneys" for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2019;8:e13351. [PMID: 31228175 DOI: 10.2196/13351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wu JF, Muthusamy A, Al-Ghalith GA, Knights D, Guo B, Wu B, Remmel RP, Schladt DP, Alegre ML, Oetting WS, Jacobson PA, Israni AK. Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients. Clin Transplant 2018;32:e13436. [PMID: 30372560 DOI: 10.1111/ctr.13436] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ball S. Bioequivalence of twice-daily oral tacrolimus in transplant recipients: More evidence for consensus? PLoS Med 2017;14:e1002429. [PMID: 29135980 DOI: 10.1371/journal.pmed.1002429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 De T, Park CS, Perera MA. Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White? Annu Rev Pharmacol Toxicol 2019;59:577-603. [PMID: 30296897 DOI: 10.1146/annurev-pharmtox-010818-021154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Sharma A, Cherukuri A, Mehta RB, Sood P, Hariharan S. High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss. Transplant Direct 2019;5:e424. [PMID: 30882028 DOI: 10.1097/TXD.0000000000000862] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Taber DJ, Su Z, Fleming JN, Pilch NA, Morinelli T, Mauldin P, Dubay D. The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. Transpl Int 2019;32:84-94. [PMID: 30176087 DOI: 10.1111/tri.13338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
20 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
21 Kuypers DRJ. Tacrolimus Formulations and African American Kidney Transplant Recipients: When Do Details Matter? Am J Kidney Dis 2018;71:302-5. [PMID: 29477174 DOI: 10.1053/j.ajkd.2017.10.020] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Mo H, Kim SY, Min S, Han A, Ahn S, Min SK, Lee H, Ahn C, Kim Y, Ha J. Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation. Transplant Direct 2019;5:e455. [PMID: 31321291 DOI: 10.1097/TXD.0000000000000899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
23 González-vílchez F, Crespo-leiro MG, Delgado-jiménez J, Pérez-villa F, Segovia-cubero J, Díaz-molina B, Mirabet-pérez S, Arizón del Prado JM, Blasco-peiró T, Martínez-sellés M, Almenar-bonet L, Garrido-bravo I, Rábago G, Vázquez de Prada JA. Impacto de la variabilidad intrapaciente en la concentración sanguínea de anticalcineurínicos en los resultados del trasplante cardiaco. Revista Española de Cardiología 2022;75:129-40. [DOI: 10.1016/j.recesp.2021.02.004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]